Intravenous ascorbic acid to prevent and treat cancer-associated sepsis?

Journal of Translational Medicine

Volumn 9, Issue , 2011, Pages

  Ichim, Thomas E ^a,b   Minev, Boris ^c   Braciak, Todd ^b,d   Luna, Brandon ^b   Hunninghake, Ron ^a   Mikirova, Nina A ^a   Jackson, James A ^a   Gonzalez, Michael J ^e   Miranda Massari, Jorge R ^f   Alexandrescu, Doru T ^g   Dasanu, Constantin A ^h   Bogin, Vladimir ^b   Ancans, Janis ⁱ   Stevens, R Brian ^j   Markosian, Boris ^b   Koropatnick, James ^k   Chen, Chien Shing ^l   Riordan, Neil H ^a,b  

^a Riordan Clinic   (United States)

^b Medistem Inc   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d TORREY PINES INSTITUTE FOR MOLECULAR STUDIES   (United States)

^e UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

^f UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^g Georgetown Dermatology   (United States)

^h UNIVERSITY OF CONNECTICUT   (United States)

ⁱ UNIVERSITY OF LATVIA   (Latvia)

^j UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^k LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

^l LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; DISEASE COURSE; DISEASE MARKER; DISEASE MODEL; ENDOTHELIUM; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE ORGAN FAILURE; NONHUMAN; REVIEW; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; ARTICLE; ASCORBIC ACID DEFICIENCY; DRUG EFFECT; IMMUNITY; INTRAVENOUS DRUG ADMINISTRATION; NEOPLASM; PATHOPHYSIOLOGY;

ASCORBIC ACID; ASCORBIC ACID DEFICIENCY; ENDOTHELIUM; HUMANS; IMMUNITY; INJECTIONS, INTRAVENOUS; NEOPLASMS; SEPSIS;

EID: 79952202672     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-9-25     Document Type: Review

References (246)

1. Dougherty CJ, Ichim TE, Liu L, Reznik G, Min WP, Ghochikyan A, Agadjanyan MG, Reznik BN. Selective apoptosis of breast cancer cells by siRNA targeting of BORIS. Biochem Biophys Res Commun 2008, 370:109-112.
2. Loukinov D, Ghochikyan A, Mkrtichyan M, Ichim TE, Lobanenkov VV, Cribbs DH, Agadjanyan MG. Antitumor efficacy of DNA vaccination to the epigenetically acting tumor promoting transcription factor BORIS and CD80 molecular adjuvant. J Cell Biochem 2006, 98:1037-1043.
3. Ghochikyan A, Mkrtichyan M, Loukinov D, Mamikonyan G, Pack SD, Movsesyan N, Ichim TE, Cribbs DH, Lobanenkov VV, Agadjanyan MG. Elicitation of T cell responses to histologically unrelated tumors by immunization with the novel cancer-testis antigen, brother of the regulator of imprinted sites. J Immunol 2007, 178:566-573.
4. Mkrtichyan M, Ghochikyan A, Loukinov D, Davtyan H, Ichim TE, Cribbs DH, Lobanenkov VV, Agadjanyan MG. DNA, but not protein vaccine based on mutated BORIS antigen significantly inhibits tumor growth and prolongs the survival of mice. Gene Ther 2008, 15:61-64.
5. Ichim TE, Zhong Z, Kaushal S, Zheng X, Ren X, Hao X, Joyce JA, Hanley HH, Riordan NH, Koropatnick J, et al. Exosomes as a tumor immune escape mechanism: possible therapeutic implications. J Transl Med 2008, 6:37.
6. Marleau AM, Lipton JH, Riordan NH, Ichim TE. Therapeutic use of Aldara in chronic myeloid leukemia. J Transl Med 2007, 5:4.
7. Ichim TE, Popov IA, Riordan NH, Izadi H, Zhong Z, Yijian L, Sher S, Oleinik EK. A novel method of modifying immune responses by vaccination with lipiodol-siRNA mixtures. J Transl Med 2006, 4:2.
8. Zhong Z, Kusznieruk KP, Popov IA, Riordan NH, Izadi H, Yijian L, Sher S, Szczurko OM, Agadjanyan MG, Tullis RH, et al. Induction of antitumor immunity through xenoplacental immunization. J Transl Med 2006, 4:22.
9. Han X, Meng X, Yin Z, Rogers A, Zhong J, Rillema P, Jackson JA, Ichim TE, Minev B, Carrier E, et al. Inhibition of intracranial glioma growth by endometrial regenerative cells. Cell Cycle 2009, 8:606-610.
10. Levenson SM, et al. Ascorbic acid r, thiamin, and nicotinic acid in relation to severe injury, hemorrhage, and infection in the human. Ann Surg 1946, 124:840-856.
11. Cameron E, Campbell A. The orthomolecular treatment of cancer. II. Clinical trial of high-dose ascorbic acid supplements in advanced human cancer. Chem Biol Interact 1974, 9:285-315.
12. Yeom CH, Jung GC, Song KJ. Changes of terminal cancer patients' health-related quality of life after high dose vitamin C administration. J Korean Med Sci 2007, 22:7-11.
13. Cameron E, Pauling L. Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer. Proc Natl Acad Sci USA 1976, 73:3685-3689.
14. Cameron and Pauling PNASUSAS-Saitstocropos.
15. Murata A, Morishige F, Yamaguchi H. Prolongation of survival times of terminal cancer patients by administration of large doses of ascorbate. Int J Vitam Nutr Res Suppl 1982, 23:103-113.
16. Creagan ET, Moertel CG, O'Fallon JR, Schutt AJ, O'Connell MJ, Rubin J, Frytak S. Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N Engl J Med 1979, 301:687-690.
17. Moertel CG, Fleming TR, Creagan ET, Rubin J, O'Connell MJ, Ames MM. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl J Med 1985, 312:137-141.
18. Duconge J, Miranda-Massari JR, Gonzalez MJ, Jackson JA, Warnock W, Riordan NH. Pharmacokinetics of vitamin C: insights into the oral and intravenous administration of ascorbate. P R Health Sci J 2008, 27:7-19.
19. Duconge J, Miranda-Massari JR, Gonzalez MJ, Taylor PR, Riordan HD, Riordan NH, Casciari JJ, Alliston K. Vitamin C pharmacokinetics after continuous infusion in a patient with prostate cancer. Ann Pharmacother 2007, 41:1082-1083.
20. Padayatty SJ, Sun H, Wang Y, Riordan HD, Hewitt SM, Katz A, Wesley RA, Levine M. Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med 2004, 140:533-537.
21. Riordan NH, Riordan HD, Meng X, Li Y, Jackson JA. Intravenous ascorbate as a tumor cytotoxic chemotherapeutic agent. Med Hypotheses 1995, 44:207-213.
22. Verrax J, Calderon PB. Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effects. Free Radic Biol Med 2009, 47:32-40.
23. Chen Q, Espey MG, Sun AY, Pooput C, Kirk KL, Krishna MC, Khosh DB, Drisko J, Levine M. Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci USA 2008, 105:11105-11109.
24. Chen Q, Espey MG, Sun AY, Lee JH, Krishna MC, Shacter E, Choyke PL, Pooput C, Kirk KL, Buettner GR, Levine M. Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc Natl Acad Sci USA 2007, 104:8749-8754.
25. Padayatty SJ, Sun AY, Chen Q, Espey MG, Drisko J, Levine M. Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects. PLoS One 5:e11414.
26. Study of High-Dose Intravenous (IV) Vitamin C Treatment in Patients With Solid Tumors. , http://www.clinicaltrials.gov/ct2/show/NCT00441207
27. Vitamin C as an Anti-cancer Drug. , http://www.clinicaltrials.gov/ct2/show/NCT01080352
28. Pilot Trial of Intravenous Vitamin C in Refractory Non-Hodgkin Lymphoma (NHL). , http://www.clinicaltrials.gov/ct2/show/NCT00626444
29. Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease. , http://www.clinicaltrials.gov/ct2/show/NCT01125449
30. Trial of Chemotherapy Plus Intravenous Vitamin C in Patients With Advanced Cancer for Whom Chemotherapy Alone is Only Marginally Effective. , http://www.clinicaltrials.gov/ct2/show/NCT01050621
31. Intravenous Vitamin C in Combination With Standard Chemotherapy for Pancreatic Cancer. , http://www.clinicaltrials.gov/ct2/show/NCT00954525
32. Polterauer S, Grimm C, Seebacher V, Rahhal J, Tempfer C, Reinthaller A, Hefler L. The inflammation-based Glasgow Prognostic Score predicts survival in patients with cervical cancer. Int J Gynecol Cancer 20:1052-1057.
33. Argiles JM, Busquets S, Toledo M, Lopez-Soriano FJ. The role of cytokines in cancer cachexia. Curr Opin Support Palliat Care 2009, 3:263-268.
34. Stephens NA, Skipworth RJ, Fearon KC. Cachexia, survival and the acute phase response. Curr Opin Support Palliat Care 2008, 2:267-274.
35. Deans C, Wigmore SJ. Systemic inflammation, cachexia and prognosis in patients with cancer. Curr Opin Clin Nutr Metab Care 2005, 8:265-269.
36. Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 6:149-163.
37. Lamb GW, McArdle PA, Ramsey S, McNichol AM, Edwards J, Aitchison M, McMillan DC. The relationship between the local and systemic inflammatory responses and survival in patients undergoing resection for localized renal cancer. BJU Int 2008, 102:756-761.
38. Ibrahim S, Claxton DF. SIRS criteria in prediction of septic shock in hospitalized patients with hematologic malignancies. Cancer Biol Ther 2009, 8:1101.
39. Nomura S, Kagawa H, Ozaki Y, Nagahama M, Yoshimura C, Fukuhara S. Relationship between platelet activation and cytokines in systemic inflammatory response syndrome patients with hematological malignancies. Thromb Res 1999, 95:205-213.
40. Regazzoni CJ, Khoury M, Irrazabal C, Myburg C, Galvalisi NR, O'Flaherty M, Sarquis SG, Poderoso JJ. Neutropenia and the development of the systemic inflammatory response syndrome. Intensive Care Med 2003, 29:135-138.
41. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992, 20:864-874.
42. Systemic Inflammatory Response Syndrome (SIRS) Prognosis. , http://www.youtube.com/watch?v=p2rEJC7He6g
43. de Jong HK, van der Poll T, Wiersinga WJ. The systemic pro-inflammatory response in sepsis. J Innate Immun 2:422-430.
44. Gando S. Disseminated intravascular coagulation in trauma patients. Semin Thromb Hemost 2001, 27:585-592.
45. Guo RF, Ward PA. C5a, a therapeutic target in sepsis. Recent Pat Antiinfect Drug Discov 2006, 1:57-65.
46. Silasi-Mansat R, Zhu H, Popescu NI, Peer G, Sfyroera G, Magotti P, Ivanciu L, Lupu C, Mollnes TE, Taylor FB, et al. Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of Escherichia coli sepsis. Blood 116:1002-1010.
47. Person AK, Kontoyiannis DP, Alexander BD. Fungal infections in transplant and oncology patients. Infect Dis Clin North Am 24:439-459.
48. Kiehn TE. Bacteremia and fungemia in the immunocompromised patient. Eur J Clin Microbiol Infect Dis 1989, 8:832-837.
49. Tisdale MJ. Cancer cachexia. Curr Opin Gastroenterol 26:26-146.
50. Gelin J, Moldawer LL, Lonnroth C, Sherry B, Chizzonite R, Lundholm K. Role of endogenous tumor necrosis factor alpha and interleukin 1 for experimental tumor growth and the development of cancer cachexia. Cancer Res 1991, 51:415-421.
51. Cahlin C, Korner A, Axelsson H, Wang W, Lundholm K, Svanberg E. Experimental cancer cachexia: the role of host-derived cytokines interleukin (IL)-6, IL-12, interferon-gamma, and tumor necrosis factor alpha evaluated in gene knockout, tumor-bearing mice on C57 Bl background and eicosanoid-dependent cachexia. Cancer Res 2000, 60:5488-5493.
52. Ely EW, Bernard GR, Vincent JL. Activated protein C for severe sepsis. N Engl J Med 2002, 347:1035-1036.
53. Dhainaut JF, Yan SB, Margolis BD, Lorente JA, Russell JA, Freebairn RC, Spapen HD, Riess H, Basson B, Johnson G, Kinasewitz GT. Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis. Thromb Haemost 2003, 90:642-653.
54. Minhas N, Xue M, Fukudome K, Jackson CJ. Activated protein C utilizes the angiopoietin/Tie2 axis to promote endothelial barrier function. FASEB J 24:24-873.
55. Loubele ST, Spronk HM, Ten Cate H. Activated protein C: a promising drug with multiple effects?. Mini Rev Med Chem 2009, 9:620-626.
56. Poole D, Bertolini G, Garattini S. Errors in the approval process and post-marketing evaluation of drotrecogin alfa (activated) for the treatment of severe sepsis. Lancet Infect Dis 2009, 9:67-72.
57. Pastores SM, Papadopoulos E, van den Brink M, Alicea M, Halpern NA. Septic shock and multiple organ failure after hematopoietic stem cell transplantation: treatment with recombinant human activated protein C. Bone Marrow Transplant 2002, 30:131-134.
58. Cristofaro P, Opal SM. The Toll-like receptors and their role in septic shock. Expert Opin Ther Targets 2003, 7:603-612.
59. Treutiger CJ, Mullins GE, Johansson AS, Rouhiainen A, Rauvala HM, Erlandsson-Harris H, Andersson U, Yang H, Tracey KJ, Andersson J, Palmblad JE. High mobility group 1 B-box mediates activation of human endothelium. J Intern Med 2003, 254:375-385.
60. Lv B, Wang H, Tang Y, Fan Z, Xiao X, Chen F. High-mobility group box 1 protein induces tissue factor expression in vascular endothelial cells via activation of NF-kappaB and Egr-1. Thromb Haemost 2009, 102:352-359.
61. Wada H, Wakita Y, Shiku H. Tissue factor expression in endothelial cells in health and disease. Blood Coagul Fibrinolysis 1995, 6(Suppl 1):S26-31.
62. Levi M. The coagulant response in sepsis and inflammation. Hamostaseologie 30:10-12. 14-16.
63. Munro JM, Pober JS, Cotran RS. Recruitment of neutrophils in the local endotoxin response: association with de novo endothelial expression of endothelial leukocyte adhesion molecule-1. Lab Invest 1991, 64:295-299.
64. Lippi G, Ippolito L, Cervellin G. Disseminated intravascular coagulation in burn injury. Semin Thromb Hemost 36:36-429.
65. Lau CL, Zhao Y, Kim J, Kron IL, Sharma A, Yang Z, Laubach VE, Linden J, Ailawadi G, Pinsky DJ. Enhanced fibrinolysis protects against lung ischemia-reperfusion injury. J Thorac Cardiovasc Surg 2009, 137:1241-1248.
66. Levi M, Schouten M, van der Poll T. Sepsis, coagulation, and antithrombin: old lessons and new insights. Semin Thromb Hemost 2008, 34:742-746.
67. Shapiro N, Schuetz P, Yano K, Sorasaki M, Parikh SM, Jones AE, Trzeciak S, Ngo L, Aird WC. The association of endothelial cell signaling, severity of illness, and organ dysfunction in sepsis. Crit Care 14:R182.
68. Druey KM, Greipp PR. Narrative review: the systemic capillary leak syndrome. Ann Intern Med 153:153-90.
69. Dejana E, Orsenigo F, Lampugnani MG. The role of adherens junctions and VE-cadherin in the control of vascular permeability. J Cell Sci 2008, 121:2115-2122.
70. Azevedo LC, Janiszewski M, Soriano FG, Laurindo FR. Redox mechanisms of vascular cell dysfunction in sepsis. Endocr Metab Immune Disord Drug Targets 2006, 6:159-164.
71. Okajima K. Prevention of endothelial cell injury by activated protein C: the molecular mechanism(s) and therapeutic implications. Curr Vasc Pharmacol 2004, 2:125-133.
72. Andersson U, Tracey KJ. HMGB1 in sepsis. Scand J Infect Dis 2003, 35:577-584.
73. Strassheim D, Park JS, Abraham E. Sepsis: current concepts in intracellular signaling. Int J Biochem Cell Biol 2002, 34:1527-1533.
74. ten Cate H, Schoenmakers SH, Franco R, Timmerman JJ, Groot AP, Spek CA, Reitsma PH. Microvascular coagulopathy and disseminated intravascular coagulation. Crit Care Med 2001, 29:S95-97. discussion S97-98.
75. Hawiger J. Innate immunity and inflammation: a transcriptional paradigm. Immunol Res 2001, 23:99-109.
76. Edgington TS, Mackman N, Fan ST, Ruf W. Cellular immune and cytokine pathways resulting in tissue factor expression and relevance to septic shock. Nouv Rev Fr Hematol 1992, 34(Suppl):S15-27.
77. Mukaida N, Ishikawa Y, Ikeda N, Fujioka N, Watanabe S, Kuno K, Matsushima K. Novel insight into molecular mechanism of endotoxin shock: biochemical analysis of LPS receptor signaling in a cell-free system targeting NF-kappaB and regulation of cytokine production/action through beta2 integrin in vivo. J Leukoc Biol 1996, 59:145-151.
78. Liu SF, Malik AB. NF-kappa B activation as a pathological mechanism of septic shock and inflammation. Am J Physiol Lung Cell Mol Physiol 2006, 290:L622-L645.
79. Ulfhammer E, Larsson P, Karlsson L, Hrafnkelsdottir T, Bokarewa M, Tarkowski A, Jern S. TNF-alpha mediated suppression of tissue type plasminogen activator expression in vascular endothelial cells is NF-kappaB- and p38 MAPK-dependent. J Thromb Haemost 2006, 4:1781-1789.
80. Xu H, Ye X, Steinberg H, Liu SF. Selective blockade of endothelial NF-kappaB pathway differentially affects systemic inflammation and multiple organ dysfunction and injury in septic mice. J Pathol 220:220-490.
81. Ding J, Song D, Ye X, Liu SF. A pivotal role of endothelial-specific NF-kappaB signaling in the pathogenesis of septic shock and septic vascular dysfunction. J Immunol 2009, 183:4031-4038.
82. Song D, Ye X, Xu H, Liu SF. Activation of endothelial intrinsic NF-{kappa}B pathway impairs protein C anticoagulation mechanism and promotes coagulation in endotoxemic mice. Blood 2009, 114:2521-2529.
83. Grinnell BW, Joyce D. Recombinant human activated protein C: a system modulator of vascular function for treatment of severe sepsis. Crit Care Med 2001, 29:S53-60. discussion S60-51.
84. Brueckmann M, Hoffmann U, De Rossi L, Weiler HM, Liebe V, Lang S, Kaden JJ, Borggrefe M, Haase KK, Huhle G. Activated protein C inhibits the release of macrophage inflammatory protein-1-alpha from THP-1 cells and from human monocytes. Cytokine 2004, 26:106-113.
85. Cheng T, Liu D, Griffin JH, Fernandez JA, Castellino F, Rosen ED, Fukudome K, Zlokovic BV. Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat Med 2003, 9:338-342.
86. van Hinsbergh VW, Bertina RM, van Wijngaarden A, van Tilburg NH, Emeis JJ, Haverkate F. Activated protein C decreases plasminogen activator-inhibitor activity in endothelial cell-conditioned medium. Blood 1985, 65:444-451.
87. Sakata Y, Curriden S, Lawrence D, Griffin JH, Loskutoff DJ. Activated protein C stimulates the fibrinolytic activity of cultured endothelial cells and decreases antiactivator activity. Proc Natl Acad Sci USA 1985, 82:1121-1125.
88. Joyce DE, Grinnell BW. Recombinant human activated protein C attenuates the inflammatory response in endothelium and monocytes by modulating nuclear factor-kappaB. Crit Care Med 2002, 30:S288-293.
89. Brueckmann M, Hoffmann U, Dvortsak E, Lang S, Kaden JJ, Borggrefe M, Haase KK. Drotrecogin alfa (activated) inhibits NF-kappa B activation and MIP-1-alpha release from isolated mononuclear cells of patients with severe sepsis. Inflamm Res 2004, 53:528-533.
90. Heitzer T, Just H, Munzel T. Antioxidant vitamin C improves endothelial dysfunction in chronic smokers. Circulation 1996, 94:6-9.
91. Chambers JC, McGregor A, Jean-Marie J, Obeid OA, Kooner JS. Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia: an effect reversible with vitamin C therapy. Circulation 1999, 99:1156-1160.
92. Timimi FK, Ting HH, Haley EA, Roddy MA, Ganz P, Creager MA. Vitamin C improves endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. J Am Coll Cardiol 1998, 31:552-557.
93. Ting HH, Timimi FK, Boles KS, Creager SJ, Ganz P, Creager MA. Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 1996, 97:22-28.
94. Solzbach U, Hornig B, Jeserich M, Just H. Vitamin C improves endothelial dysfunction of epicardial coronary arteries in hypertensive patients. Circulation 1997, 96:1513-1519.
95. Gao Y. The multiple actions of NO. Pflugers Arch 459:459-829.
96. Jackson WF. The endothelium-derived relaxing factor. J Reconstr Microsurg 1989, 5:263-271.
97. De Cruz SJ, Kenyon NJ, Sandrock CE. Bench-to-bedside review: the role of nitric oxide in sepsis. Expert Rev Respir Med 2009, 3:511-521.
98. Tyml K, Li F, Wilson JX. Septic impairment of capillary blood flow requires nicotinamide adenine dinucleotide phosphate oxidase but not nitric oxide synthase and is rapidly reversed by ascorbate through an endothelial nitric oxide synthase-dependent mechanism. Crit Care Med 2008, 36:2355-2362.
99. Naseem KM. The role of nitric oxide in cardiovascular diseases. Mol Aspects Med 2005, 26:33-65.
100. Parratt JR. Nitric oxide in sepsis and endotoxaemia. J Antimicrob Chemother 1998, 41(Suppl A):31-39.
101. Wu F, Tyml K, Wilson JX. Ascorbate inhibits iNOS expression in endotoxin- and IFN gamma-stimulated rat skeletal muscle endothelial cells. FEBS Lett 2002, 520:122-126.
102. Wu F, Wilson JX, Tyml K. Ascorbate inhibits iNOS expression and preserves vasoconstrictor responsiveness in skeletal muscle of septic mice. Am J Physiol Regul Integr Comp Physiol 2003, 285:R50-56.
103. Ulker S, McKeown PP, Bayraktutan U. Vitamins reverse endothelial dysfunction through regulation of eNOS and NAD(P)H oxidase activities. Hypertension 2003, 41:534-539.
104. Peluffo G, Calcerrada P, Piacenza L, Pizzano N, Radi R. Superoxide-mediated inactivation of nitric oxide and peroxynitrite formation by tobacco smoke in vascular endothelium: studies in cultured cells and smokers. Am J Physiol Heart Circ Physiol 2009, 296:H1781-1792.
105. May JM, Qu ZC, Li X. Ascorbic acid blunts oxidant stress due to menadione in endothelial cells. Arch Biochem Biophys 2003, 411:136-144.
106. Heller R, Munscher-Paulig F, Grabner R, Till U. L-Ascorbic acid potentiates nitric oxide synthesis in endothelial cells. J Biol Chem 1999, 274:8254-8260.
107. Nakai K, Urushihara M, Kubota Y, Kosaka H. Ascorbate enhances iNOS activity by increasing tetrahydrobiopterin in RAW 264.7 cells. Free Radic Biol Med 2003, 35:929-937.
108. d'Uscio LV, Milstien S, Richardson D, Smith L, Katusic ZS. Long-term vitamin C treatment increases vascular tetrahydrobiopterin levels and nitric oxide synthase activity. Circ Res 2003, 92:88-95.
109. Toth M, Kukor Z, Valent S. Chemical stabilization of tetrahydrobiopterin by L-ascorbic acid: contribution to placental endothelial nitric oxide synthase activity. Mol Hum Reprod 2002, 8:271-280.
110. Patel KB, Stratford MR, Wardman P, Everett SA. Oxidation of tetrahydrobiopterin by biological radicals and scavenging of the trihydrobiopterin radical by ascorbate. Free Radic Biol Med 2002, 32:203-211.
111. Stone KJ, Townsley BH. The effect of L-ascorbate on catecholamine biosynthesis. Biochem J 1973, 131:611-613.
112. Huang A, Vita JA, Venema RC, Keaney JF. Ascorbic acid enhances endothelial nitric-oxide synthase activity by increasing intracellular tetrahydrobiopterin. J Biol Chem 2000, 275:17399-17406.
113. Schmidt TS, Alp NJ. Mechanisms for the role of tetrahydrobiopterin in endothelial function and vascular disease. Clin Sci (Lond) 2007, 113:47-63.
114. Keel M, Trentz O. Pathophysiology of polytrauma. Injury 2005, 36:691-709.
115. Rossig L, Hoffmann J, Hugel B, Mallat Z, Haase A, Freyssinet JM, Tedgui A, Aicher A, Zeiher AM, Dimmeler S. Vitamin C inhibits endothelial cell apoptosis in congestive heart failure. Circulation 2001, 104:2182-2187.
116. Haendeler J, Zeiher AM, Dimmeler S. Vitamin C and E prevent lipopolysaccharide-induced apoptosis in human endothelial cells by modulation of Bcl-2 and Bax. Eur J Pharmacol 1996, 317:407-411.
117. Saeed RW, Peng T, Metz CN. Ascorbic acid blocks the growth inhibitory effect of tumor necrosis factor-alpha on endothelial cells. Exp Biol Med (Maywood) 2003, 228:855-865.
118. Fiorito C, Rienzo M, Crimi E, Rossiello R, Balestrieri ML, Casamassimi A, Muto F, Grimaldi V, Giovane A, Farzati B, et al. Antioxidants increase number of progenitor endothelial cells through multiple gene expression pathways. Free Radic Res 2008, 42:754-762.
119. Mo SJ, Son EW, Rhee DK, Pyo S. Modulation of TNF-alpha-induced ICAM-1 expression, NO and H2O2 production by alginate, allicin and ascorbic acid in human endothelial cells. Arch Pharm Res 2003, 26:244-251.
120. Martin WJ. Neutrophils kill pulmonary endothelial cells by a hydrogen-peroxide-dependent pathway. An in vitro model of neutrophil-mediated lung injury. Am Rev Respir Dis 1984, 130:209-213.
121. Chen YH, Lin SJ, Chen YL, Liu PL, Chen JW. Anti-inflammatory effects of different drugs/agents with antioxidant property on endothelial expression of adhesion molecules. Cardiovasc Hematol Disord Drug Targets 2006, 6:279-304.
122. May JM, Qu ZC. Ascorbic acid prevents increased endothelial permeability caused by oxidized low density lipoprotein. Free Radic Res 44:44-1359.
123. Wilson JX. Mechanism of action of vitamin C in sepsis: ascorbate modulates redox signaling in endothelium. Biofactors 2009, 35:5-13.
124. Utoguchi N, Ikeda K, Saeki K, Oka N, Mizuguchi H, Kubo K, Nakagawa S, Mayumi T. Ascorbic acid stimulates barrier function of cultured endothelial cell monolayer. J Cell Physiol 1995, 163:393-399.
125. Bowie A, O'Neill LA. Vitamin C inhibits NF kappa B activation in endothelial cells. Biochem Soc Trans 1997, 25:131S.
126. Carcamo JM, Pedraza A, Borquez-Ojeda O, Golde DW. Vitamin C suppresses TNF alpha-induced NF kappa B activation by inhibiting I kappa B alpha phosphorylation. Biochemistry 2002, 41:12995-13002.
127. Bowie AG, O'Neill LA. Vitamin C inhibits NF-kappa B activation by TNF via the activation of p38 mitogen-activated protein kinase. J Immunol 2000, 165:7180-7188.
128. Rodriguez-Porcel M, Lerman LO, Holmes DR, Richardson D, Napoli C, Lerman A. Chronic antioxidant supplementation attenuates nuclear factor-kappa B activation and preserves endothelial function in hypercholesterolemic pigs. Cardiovasc Res 2002, 53:1010-1018.
129. Chade AR, Rodriguez-Porcel M, Herrmann J, Zhu X, Grande JP, Napoli C, Lerman A, Lerman LO. Antioxidant intervention blunts renal injury in experimental renovascular disease. J Am Soc Nephrol 2004, 15:958-966.
130. Levine M, Conry-Cantilena C, Wang Y, Welch RW, Washko PW, Dhariwal KR, Park JB, Lazarev A, Graumlich JF, King J, Cantilena LR. Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Proc Natl Acad Sci USA 1996, 93:3704-3709.
131. Hathcock JN, Azzi A, Blumberg J, Bray T, Dickinson A, Frei B, Jialal I, Johnston CS, Kelly FJ, Kraemer K, et al. Vitamins E and C are safe across a broad range of intakes. Am J Clin Nutr 2005, 81:736-745.
132. Eskurza I, Monahan KD, Robinson JA, Seals DR. Effect of acute and chronic ascorbic acid on flow-mediated dilatation with sedentary and physically active human ageing. J Physiol 2004, 556:315-324.
133. McGregor GP, Biesalski HK. Rationale and impact of vitamin C in clinical nutrition. Curr Opin Clin Nutr Metab Care 2006, 9:697-703.
134. Schorah CJ, Downing C, Piripitsi A, Gallivan L, Al-Hazaa AH, Sanderson MJ, Bodenham A. Total vitamin C, ascorbic acid, and dehydroascorbic acid concentrations in plasma of critically ill patients. Am J Clin Nutr 1996, 63:760-765.
135. Sinclair AJ, Taylor PB, Lunec J, Girling AJ, Barnett AH. Low plasma ascorbate levels in patients with type 2 diabetes mellitus consuming adequate dietary vitamin C. Diabet Med 1994, 11:893-898.
136. Du WD, Yuan ZR, Sun J, Tang JX, Cheng AQ, Shen DM, Huang CJ, Song XH, Yu XF, Zheng SB. Therapeutic efficacy of high-dose vitamin C on acute pancreatitis and its potential mechanisms. World J Gastroenterol 2003, 9:2565-2569.
137. Bakaev VV, Duntau AP. Ascorbic acid in blood serum of patients with pulmonary tuberculosis and pneumonia. Int J Tuberc Lung Dis 2004, 8:263-266.
138. Maggio D, Barabani M, Pierandrei M, Polidori MC, Catani M, Mecocci P, Senin U, Pacifici R, Cherubini A. Marked decrease in plasma antioxidants in aged osteoporotic women: results of a cross-sectional study. J Clin Endocrinol Metab 2003, 88:1523-1527.
139. Lunec J, Blake DR. The determination of dehydroascorbic acid and ascorbic acid in the serum and synovial fluid of patients with rheumatoid arthritis (RA). Free Radic Res Commun 1985, 1:31-39.
140. Fain O, Mathieu E, Thomas M. Scurvy in patients with cancer. BMJ 1998, 316:1661-1662.
141. Mayland CR, Bennett MI, Allan K. Vitamin C deficiency in cancer patients. Palliat Med 2005, 19:17-20.
142. Bodansky O, Wroblewski F, Markardt B. Concentrations of ascorbic acid in plasma and white blood cells of patients with cancer and noncancerous chronic disease. Cancer 1952, 5:678-684.
143. Butcher RG, Chayen J. Oxidation of L-ascorbic acid by cells of carcinoma of the human cervix. Nature 1965, 207:992-993.
144. Fraenkel-Conrat J, Stoy T, Tsai SF. Investigation of ascorbic acid levels in blood of cancer patients compared to normal subjects. Mo Med 1967, 64:1001-1002.
145. Anthony HM, Schorah CJ. Severe hypovitaminosis C in lung-cancer patients: the utilization of vitamin C in surgical repair and lymphocyte-related host resistance. Br J Cancer 1982, 46:354-367.
146. Gupta A, Bhatt ML, Misra MK. Lipid peroxidation and antioxidant status in head and neck squamous cell carcinoma patients. Oxid Med Cell Longev 2009, 2:68-72.
147. Long CL, Maull KI, Krishnan RS, Laws HL, Geiger JW, Borghesi L, Franks W, Lawson TC, Sauberlich HE. Ascorbic acid dynamics in the seriously ill and injured. J Surg Res 2003, 109:144-148.
148. Kuiper C, Molenaar IG, Dachs GU, Currie MJ, Sykes PH, Vissers MC. Low ascorbate levels are associated with increased hypoxia-inducible factor-1 activity and an aggressive tumor phenotype in endometrial cancer. Cancer Res 70:70-5749.
149. Ghezzi F, Cromi A, Siesto G, Giudici S, Serati M, Formenti G, Franchi M. Prognostic significance of preoperative plasma fibrinogen in endometrial cancer. Gynecol Oncol 119:119-309.
150. Tang L, Liu K, Wang J, Wang C, Zhao P, Liu J. High preoperative plasma fibrinogen levels are associated with distant metastases and impaired prognosis after curative resection in patients with colorectal cancer. J Surg Oncol 102:102-428.
151. Polterauer S, Grimm C, Seebacher V, Concin N, Marth C, Tomovski C, Husslein H, Leipold H, Hefler-Frischmuth K, Tempfer C, et al. Plasma fibrinogen levels and prognosis in patients with ovarian cancer: a multicenter study. Oncologist 2009, 14:979-985.
152. Zhu WL, Fan BL, Liu DL, Zhu WX. Abnormal expression of fibrinogen gamma (FGG) and plasma level of fibrinogen in patients with hepatocellular carcinoma. Anticancer Res 2009, 29:2531-2534.
153. Polterauer S, Seebacher V, Hefler-Frischmuth K, Grimm C, Heinze G, Tempfer C, Reinthaller A, Hefler L. Fibrinogen plasma levels are an independent prognostic parameter in patients with cervical cancer. Am J Obstet Gynecol 2009, 200:e641-647.
154. Guo Q, Zhang B, Dong X, Xie Q, Guo E, Huang H, Wu Y. Elevated levels of plasma fibrinogen in patients with pancreatic cancer: possible role of a distant metastasis predictor. Pancreas 2009, 38:e75-79.
155. Takeuchi H, Ikeuchi S, Kitagawa Y, Shimada A, Oishi T, Isobe Y, Kubochi K, Kitajima M, Matsumoto S. Pretreatment plasma fibrinogen level correlates with tumor progression and metastasis in patients with squamous cell carcinoma of the esophagus. J Gastroenterol Hepatol 2007, 22:2222-2227.
156. Lukaszewicz-Zajac M, Mroczko B, Gryko M, Kedra B, Szmitkowski M. Comparison between clinical significance of serum proinflammatory proteins (IL-6 and CRP) and classic tumor markers (CEA and CA 19-9) in gastric cancer. Clin Exp Med 2010,
157. Kanz R, Vukovich T, Vormittag R, Dunkler D, Ay C, Thaler J, Haselbock J, Scheithauer W, Zielinski C, Pabinger I. Thrombosis risk and survival in cancer patients with elevated C-reactive protein. J Thromb Haemost 2011, 9(1):57-63.
158. Kocsis J, Meszaros T, Madaras B, Toth EK, Kamondi S, Gal P, Varga L, Prohaszka Z, Fust G. High levels of acute phase proteins and soluble 70 kDa heat shock proteins are independent and additive risk factors for mortality in colorectal cancer. Cell Stress Chaperones 2011, 16(1):49-55. Epub 2010 Aug 22.
159. Prins RC, Rademacher BL, Mongoue-Tchokote S, Alumkal JJ, Graff JN, Eilers KM, Beer TM. C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): Confirmatory results. Urol Oncol 2010,
160. Wang CS, Sun CF. C-reactive protein and malignancy: clinico-pathological association and therapeutic implication. Chang Gung Med J 2009, 32:471-482.
161. Schroecksnadel K, Frick B, Fiegl M, Winkler C, Denz HA, Fuchs D. Hyperhomocysteinaemia and immune activation in patients with cancer. Clin Chem Lab Med 2007, 45:47-53.
162. Miyata Y, Koga S, Nishikido M, Noguchi M, Kanda S, Hayashi T, Saito Y, Kanetake H. Predictive values of acute phase reactants, basic fetoprotein, and immunosuppressive acidic protein for staging and survival in renal cell carcinoma. Urology 2001, 58:161-164.
163. Song MK, Chung JS, Seol YM, Shin HJ, Choi YJ, Cho GJ. Elevation of serum ferritin is associated with the outcome of patients with newly diagnosed multiple myeloma. Korean J Intern Med 2009, 24:368-373.
164. Singh KJ, Singh SK, Suri A, Vijjan V, Goswami AK, Khullar M. Serum ferritin in renal cell carcinoma: effect of tumor size, volume grade, and stage. Indian J Cancer 2005, 42:197-200.
165. Garaventa A, Boni L, Lo Piccolo MS, Tonini GP, Gambini C, Mancini A, Tonegatti L, Carli M, di Montezemolo LC, Di Cataldo A, et al. Localized unresectable neuroblastoma: results of treatment based on clinical prognostic factors. Ann Oncol 2002, 13:956-964.
166. Sucher R, Schroecksnadel K, Weiss G, Margreiter R, Fuchs D, Brandacher G. Neopterin, a prognostic marker in human malignancies. Cancer Lett 287:287-13.
167. Melichar B, Solichova D, Freedman RS. Neopterin as an indicator of immune activation and prognosis in patients with gynecological malignancies. Int J Gynecol Cancer 2006, 16:240-252.
168. Murr C, Fuith LC, Widner B, Wirleitner B, Baier-Bitterlich G, Fuchs D. Increased neopterin concentrations in patients with cancer: indicator of oxidative stress?. Anticancer Res 1999, 19:1721-1728.
169. Ferroni P, Palmirotta R, Martini F, Riondino S, Savonarola A, Spila A, Ciatti F, Sini V, Mariotti S, Del Monte G, et al. Determinants of homocysteine levels in colorectal and breast cancer patients. Anticancer Res 2009, 29:4131-4138.
170. Almadori G, Bussu F, Galli J, Cadoni G, Zappacosta B, Persichilli S, Minucci A, Giardina B, Maurizi M. Serum levels of folate, homocysteine, and vitamin B12 in head and neck squamous cell carcinoma and in laryngeal leukoplakia. Cancer 2005, 103:284-292.
171. Blay JY, Negrier S, Combaret V, Attali S, Goillot E, Merrouche Y, Mercatello A, Ravault A, Tourani JM, Moskovtchenko JF, et al. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 1992, 52:3317-3322.
172. Salzman R, Pacal L, Tomandl J, Kankova K, Tothova E, Gal B, Kostrica R, Salzman P. Elevated malondialdehyde correlates with the extent of primary tumor and predicts poor prognosis of oropharyngeal cancer. Anticancer Res 2009, 29:4227-4231.
173. Arsova-Sarafinovska Z, Eken A, Matevska N, Erdem O, Sayal A, Savaser A, Banev S, Petrovski D, Dzikova S, Georgiev V, et al. Increased oxidative/nitrosative stress and decreased antioxidant enzyme activities in prostate cancer. Clin Biochem 2009, 42:1228-1235.
174. Patel BP, Rawal UM, Dave TK, Rawal RM, Shukla SN, Shah PM, Patel PS. Lipid peroxidation, total antioxidant status, and total thiol levels predict overall survival in patients with oral squamous cell carcinoma. Integr Cancer Ther 2007, 6:365-372.
175. Ray G, Batra S, Shukla NK, Deo S, Raina V, Ashok S, Husain SA. Lipid peroxidation, free radical production and antioxidant status in breast cancer. Breast Cancer Res Treat 2000, 59:163-170.
176. Fain O, Paries J, Jacquart B, Le Moel G, Kettaneh A, Stirnemann J, Heron C, Sitbon M, Taleb C, Letellier E, et al. Hypovitaminosis C in hospitalized patients. Eur J Intern Med 2003, 14:419-425.
177. Kubota Y, Moriyama Y, Yamagishi K, Tanigawa T, Noda H, Yokota K, Harada M, Inagawa M, Oshima M, Sato S, Iso H. Serum vitamin C concentration and hs-CRP level in middle-aged Japanese men and women. Atherosclerosis 208:208-496.
178. Block G, Jensen CD, Dalvi TB, Norkus EP, Hudes M, Crawford PB, Holland N, Fung EB, Schumacher L, Harmatz P. Vitamin C treatment reduces elevated C-reactive protein. Free Radic Biol Med 2009, 46:70-77.
179. Mayland C, Allen KR, Degg TJ, Bennet M. Micronutrient concentrations in patients with malignant disease: effect of the inflammatory response. Ann Clin Biochem 2004, 41:138-141.
180. Kaehler J, Koeke K, Karstens M, Schneppenheim R, Meinertz T, Heitzer T. Impaired capacity for acute endogenous fibrinolysis in smokers is restored by ascorbic acid. Free Radic Biol Med 2008, 44:315-321.
181. Korantzopoulos P, Kolettis TM, Kountouris E, Dimitroula V, Karanikis P, Pappa E, Siogas K, Goudevenos JA. Oral vitamin C administration reduces early recurrence rates after electrical cardioversion of persistent atrial fibrillation and attenuates associated inflammation. Int J Cardiol 2005, 102:321-326.
182. Bohm F, Settergren M, Pernow J. Vitamin C blocks vascular dysfunction and release of interleukin-6 induced by endothelin-1 in humans in vivo. Atherosclerosis 2007, 190:408-415.
183. Murr C, Winklhofer-Roob BM, Schroecksnadel K, Maritschnegg M, Mangge H, Bohm BO, Winkelmann BR, Marz W, Fuchs D. Inverse association between serum concentrations of neopterin and antioxidants in patients with and without angiographic coronary artery disease. Atherosclerosis 2009, 202:543-549.
184. Doise JM, Aho LS, Quenot JP, Guilland JC, Zeller M, Vergely C, Aube H, Blettery B, Rochette L. Plasma antioxidant status in septic critically ill patients: a decrease over time. Fundam Clin Pharmacol 2008, 22:203-209.
185. Borrelli E, Roux-Lombard P, Grau GE, Girardin E, Ricou B, Dayer J, Suter PM. Plasma concentrations of cytokines, their soluble receptors, and antioxidant vitamins can predict the development of multiple organ failure in patients at risk. Crit Care Med 1996, 24:392-397.
186. Galley HF, Davies MJ, Webster NR. Ascorbyl radical formation in patients with sepsis: effect of ascorbate loading. Free Radic Biol Med 1996, 20:139-143.
187. Gaut JP, Belaaouaj A, Byun J, Roberts LJ, Maeda N, Frei B, Heinecke JW. Vitamin C fails to protect amino acids and lipids from oxidation during acute inflammation. Free Radic Biol Med 2006, 40:1494-1501.
188. Shen KP, Lo YC, Yang RC, Liu HW, Chen IJ, Wu BN. Antioxidant eugenosedin-A protects against lipopolysaccharide-induced hypotension, hyperglycaemia and cytokine immunoreactivity in rats and mice. J Pharm Pharmacol 2005, 57:117-125.
189. Tyml K, Li F, Wilson JX. Delayed ascorbate bolus protects against maldistribution of microvascular blood flow in septic rat skeletal muscle. Crit Care Med 2005, 33:1823-1828.
190. Wu F, Wilson JX, Tyml K. Ascorbate protects against impaired arteriolar constriction in sepsis by inhibiting inducible nitric oxide synthase expression. Free Radic Biol Med 2004, 37:1282-1289.
191. Crimi E, Liguori A, Condorelli M, Cioffi M, Astuto M, Bontempo P, Pignalosa O, Vietri MT, Molinari AM, Sica V, et al. The beneficial effects of antioxidant supplementation in enteral feeding in critically ill patients: a prospective, randomized, double-blind, placebo-controlled trial. Anesth Analg 2004, 99:857-863. table of contents.
192. Nathens AB, Neff MJ, Jurkovich GJ, Klotz P, Farver K, Ruzinski JT, Radella F, Garcia I, Maier RV. Randomized, prospective trial of antioxidant supplementation in critically ill surgical patients. Ann Surg 2002, 236:814-822.
193. Tanaka H, Matsuda T, Miyagantani Y, Yukioka T, Matsuda H, Shimazaki S. Reduction of resuscitation fluid volumes in severely burned patients using ascorbic acid administration: a randomized, prospective study. Arch Surg 2000, 135:326-331.
194. Deubzer B, Mayer F, Kuci Z, Niewisch M, Merkel G, Handgretinger R, Bruchelt G. H(2)O(2)-mediated cytotoxicity of pharmacologic ascorbate concentrations to neuroblastoma cells: potential role of lactate and ferritin. Cell Physiol Biochem 25:25-767.
195. Gilloteaux J, Jamison JM, Neal DR, Loukas M, Doberzstyn T, Summers JL. Cell damage and death by autoschizis in human bladder (RT4) carcinoma cells resulting from treatment with ascorbate and menadione. Ultrastruct Pathol 34:34-140.
196. Cullen JJ. Ascorbate induces autophagy in pancreatic cancer. Autophagy 6:6-421.
197. Takemura Y, Satoh M, Satoh K, Hamada H, Sekido Y, Kubota S. High dose of ascorbic acid induces cell death in mesothelioma cells. Biochem Biophys Res Commun 394:394-249.
198. Verrax J, Pedrosa RC, Beck R, Dejeans N, Taper H, Calderon PB. In situ modulation of oxidative stress: a novel and efficient strategy to kill cancer cells. Curr Med Chem 2009, 16:1821-1830.
199. Fromberg A, Gutsch D, Schulze D, Vollbracht C, Weiss G, Czubayko F, Aigner A. Ascorbate exerts anti-proliferative effects through cell cycle inhibition and sensitizes tumor cells towards cytostatic drugs. Cancer Chemother Pharmacol 2010,
200. Pollard HB, Levine MA, Eidelman O, Pollard M. Pharmacological ascorbic acid suppresses syngeneic tumor growth and metastases in hormone-refractory prostate cancer. In Vivo 24:24-249.
201. Padayatty SJ, Riordan HD, Hewitt SM, Katz A, Hoffer LJ, Levine M. Intravenously administered vitamin C as cancer therapy: three cases. CMAJ 2006, 174:937-942.
202. Mikirova NA, Ichim TE, Riordan NH. Anti-angiogenic effect of high doses of ascorbic acid. J Transl Med 2008, 6:50.
203. Ashino H, Shimamura M, Nakajima H, Dombou M, Kawanaka S, Oikawa T, Iwaguchi T, Kawashima S. Novel function of ascorbic acid as an angiostatic factor. Angiogenesis 2003, 6:259-269.
204. Mikirova NA, Casciari JJ, Riordan NH. Ascorbate inhibition of angiogenesis in aortic rings ex vivo and subcutaneous Matrigel plugs in vivo. J Angiogenes Res 2:2.
205. Yeom CH, Lee G, Park JH, Yu J, Park S, Yi SY, Lee HR, Hong YS, Yang J, Lee S. High dose concentration administration of ascorbic acid inhibits tumor growth in BALB/C mice implanted with sarcoma 180 cancer cells via the restriction of angiogenesis. J Transl Med 2009, 7:70.
206. Muellner MK, Schreier SM, Schmidbauer B, Moser M, Quehenberger P, Kapiotis S, Goldenberg H, Laggner H. Vitamin C inhibits NO-induced stabilization of HIF-1alpha in HUVECs. Free Radic Res 44:44-783.
207. Horak P, Crawford AR, Vadysirisack DD, Nash ZM, DeYoung MP, Sgroi D, Ellisen LW. Negative feedback control of HIF-1 through REDD1-regulated ROS suppresses tumorigenesis. Proc Natl Acad Sci USA 107:4675-4680.
208. Gao P, Zhang H, Dinavahi R, Li F, Xiang Y, Raman V, Bhujwalla ZM, Felsher DW, Cheng L, Pevsner J, et al. HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell 2007, 12:230-238.
209. Tatla S, Woodhead V, Foreman JC, Chain BM. The role of reactive oxygen species in triggering proliferation and IL-2 secretion in T cells. Free Radic Biol Med 1999, 26:14-24.
210. Williams MS, Kwon J. T cell receptor stimulation, reactive oxygen species, and cell signaling. Free Radic Biol Med 2004, 37:1144-1151.
211. Schwager J, Schulze J. Influence of ascorbic acid on the response to mitogens and interleukin production of porcine lymphocytes. Int J Vitam Nutr Res 1997, 67:10-16.
212. Eylar E, Baez I, Navas J, Mercado C. Sustained levels of ascorbic acid are toxic and immunosuppressive for human T cells. P R Health Sci J 1996, 15:21-26.
213. Huwyler T, Hirt A, Morell A. Effect of ascorbic acid on human natural killer cells. Immunol Lett 1985, 10:173-176.
214. Tan PH, Sagoo P, Chan C, Yates JB, Campbell J, Beutelspacher SC, Foxwell BM, Lombardi G, George AJ. Inhibition of NF-kappa B and oxidative pathways in human dendritic cells by antioxidative vitamins generates regulatory T cells. J Immunol 2005, 174:7633-7644.
215. Chen S, Yang L, Li Y. TCR zeta chain expression in T cells from patients with CML. Hematology 2009, 14:95-100.
216. Kulkarni DP, Wadia PP, Pradhan TN, Pathak AK, Chiplunkar SV. Mechanisms involved in the down-regulation of TCR zeta chain in tumor versus peripheral blood of oral cancer patients. Int J Cancer 2009, 124:1605-1613.
217. Gruber IV, El Yousfi S, Durr-Storzer S, Wallwiener D, Solomayer EF, Fehm T. Down-regulation of CD28, TCR-zeta (zeta) and up-regulation of FAS in peripheral cytotoxic T-cells of primary breast cancer patients. Anticancer Res 2008, 28:779-784.
218. Pignataro L, Pagani D, Brando B, Sambataro G, Scarpati B, Corsi MM. Down-regulation of zeta chain and zeta-associated protein 70 (Zap 70) expression in circulating T lymphocytes in laryngeal squamous cell carcinoma. Anal Quant Cytol Histol 2007, 29:57-62.
219. Zehbe I, Schmidt M, Maeurer M, Leo C, Hockel M, Pilch H. Different T-cell receptor (TCR) zeta chain expression in cervical cancer and its precursor lesions. Zentralbl Gynakol 2006, 128:266-270.
220. Ciszak L, Pawlak E, Kosmaczewska A, Potoczek S, Frydecka I. Alterations in the expression of signal-transducing CD3 zeta chain in T cells from patients with chronic inflammatory/autoimmune diseases. Arch Immunol Ther Exp (Warsz) 2007, 55:373-386.
221. Baniyash M. TCR zeta-chain downregulation: curtailing an excessive inflammatory immune response. Nat Rev Immunol 2004, 4:675-687.
222. Pitcher LA, van Oers NS. T-cell receptor signal transmission: who gives an ITAM?. Trends Immunol 2003, 24:554-560.
223. Gastman BR, Johnson DE, Whiteside TL, Rabinowich H. Tumor-induced apoptosis of T lymphocytes: elucidation of intracellular apoptotic events. Blood 2000, 95:2015-2023.
224. Boussiotis VA, Barber DL, Lee BJ, Gribben JG, Freeman GJ, Nadler LM. Differential association of protein tyrosine kinases with the T cell receptor is linked to the induction of anergy and its prevention by B7 family-mediated costimulation. J Exp Med 1996, 184:365-376.
225. Kim CW, Choi SH, Chung EJ, Lee MJ, Byun EK, Ryu MH, Bang YJ. Alteration of signal-transducing molecules and phenotypical characteristics in peripheral blood lymphocytes from gastric carcinoma patients. Pathobiology 1999, 67:123-128.
226. Reichert TE, Day R, Wagner EM, Whiteside TL. Absent or low expression of the zeta chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma. Cancer Res 1998, 58:5344-5347.
227. Zea AH, Curti BD, Longo DL, Alvord WG, Strobl SL, Mizoguchi H, Creekmore SP, O'Shea JJ, Powers GC, Urba WJ, et al. Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin Cancer Res 1995, 1:1327-1335.
228. Healy CG, Simons JW, Carducci MA, DeWeese TL, Bartkowski M, Tong KP, Bolton WE. Impaired expression and function of signal-transducing zeta chains in peripheral T cells and natural killer cells in patients with prostate cancer. Cytometry 1998, 32:109-119.
229. Mulder WM, Bloemena E, Stukart MJ, Kummer JA, Wagstaff J, Scheper RJ. T cell receptor-zeta and granzyme B expression in mononuclear cell infiltrates in normal colon mucosa and colon carcinoma. Gut 1997, 40:113-119.
230. Muller D, Lang S, Roskrow M, Wollenberg B. [The expression of zeta-chain of the T cell receptor as prognostic marker for patients with head and neck cancer]. Laryngorhinootologie 2002, 81:516-520.
231. Whiteside TL. Down-regulation of zeta-chain expression in T cells: a biomarker of prognosis in cancer?. Cancer Immunol Immunother 2004, 53:865-878.
232. Eleftheriadis T, Kartsios C, Yiannaki E, Antoniadi G, Kazila P, Pliakos K, Liakopoulos V, Markala D. Decreased CD3+CD16+ natural killer-like T-cell percentage and zeta-chain expression accompany chronic inflammation in haemodialysis patients. Nephrology (Carlton) 2009, 14:471-475.
233. Eleftheriadis T, Kartsios C, Yiannaki E, Kazila P, Antoniadi G, Liakopoulos V, Markala D. Chronic inflammation and CD16+ natural killer cell zeta-chain downregulation in hemodialysis patients. Blood Purif 2008, 26:317-321.
234. Nambiar MP, Krishnan S, Warke VG, Tsokos GC. TCR zeta-chain abnormalities in human systemic lupus erythematosus. Methods Mol Med 2004, 102:49-72.
235. Takeuchi T, Tsuzaka K, Abe T, Yoshimoto K, Shiraishi K, Kameda H, Amano K. T cell abnormalities in systemic lupus erythematosus. Autoimmunity 2005, 38:339-346.
236. Berg L, Ronnelid J, Klareskog L, Bucht A. Down-regulation of the T cell receptor CD3 zeta chain in rheumatoid arthritis (RA) and its influence on T cell responsiveness. Clin Exp Immunol 2000, 120:174-182.
237. Maurice MM, Lankester AC, Bezemer AC, Geertsma MF, Tak PP, Breedveld FC, van Lier RA, Verweij CL. Defective TCR-mediated signaling in synovial T cells in rheumatoid arthritis. J Immunol 1997, 159:2973-2978.
238. Ammirati E, Vermi AC, Cianflone D, Banfi M, Foglieni C, Godino C, Airoldi F, Ferri LA, Gorman CL, Manfredi AA, et al. Expansion of T-cell receptor zeta dim effector T cells in acute coronary syndromes. Arterioscler Thromb Vasc Biol 2008, 28:2305-2311.
239. Sikora J, Dworacki G, Giersz R, Zeromski J. The role of monocytes/macrophages in TCR-zeta chain downregulation and apoptosis of T lymphocytes in malignant pleural effusions. J Biol Regul Homeost Agents 2004, 18:26-32.
240. Markiewski MM, DeAngelis RA, Benencia F, Ricklin-Lichtsteiner SK, Koutoulaki A, Gerard C, Coukos G, Lambris JD. Modulation of the antitumor immune response by complement. Nat Immunol 2008, 9:1225-1235.
241. Corzo CA, Cotter MJ, Cheng P, Cheng F, Kusmartsev S, Sotomayor E, Padhya T, McCaffrey TV, McCaffrey JC, Gabrilovich DI. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J Immunol 2009, 182:5693-5701.
242. Choi JY, Oughton JA, Kerkvliet NI. Functional alterations in CD11b(+)Gr-1(+) cells in mice injected with allogeneic tumor cells and treated with 2,3,7,8-tetrachlorodibenzo-p-dioxin. Int Immunopharmacol 2003, 3:553-570.
243. Makarenkova VP, Bansal V, Matta BM, Perez LA, Ochoa JB. CD11b+/Gr-1+ myeloid suppressor cells cause T cell dysfunction after traumatic stress. J Immunol 2006, 176:2085-2094.
244. Ezernitchi AV, Vaknin I, Cohen-Daniel L, Levy O, Manaster E, Halabi A, Pikarsky E, Shapira L, Baniyash M. TCR zeta down-regulation under chronic inflammation is mediated by myeloid suppressor cells differentially distributed between various lymphatic organs. J Immunol 2006, 177:4763-4772.
245. Schmielau J, Finn OJ. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res 2001, 61:4756-4760.
246. Nambiar MP, Fisher CU, Enyedy EJ, Warke VG, Kumar A, Tsokos GC. Oxidative stress is involved in the heat stress-induced downregulation of TCR zeta chain expression and TCR/CD3-mediated [Ca(2+)](i) response in human T-lymphocytes. Cell Immunol 2002, 215:151-161.